The field of cell therapy, initially heralded as a revolutionary frontier in biotechnology, is now grappling with considerable hurdles that threaten its progress and market penetration. Known for pioneering treatments like CAR-T cell therapy, which modifies a patient's T-cells to combat cancer more
Spur Therapeutics, previously known as Freeline Therapeutics, is making waves in the field of genetic medicine with its rebranding and renewed mission to revolutionize the treatment of chronic diseases through gene therapy. The company's ambitious initiatives encompass innovative research,
Freeline Therapeutics, known for its pioneering work in gene therapy, has unveiled a new identity and an expanded mission, rebranding itself as Spur Therapeutics. This transformation marks a significant step towards a broader and more ambitious vision that includes tackling both rare genetic
Advancements in cancer treatments have always been a focal point in medical research. Mustang Bio, Inc. (Nasdaq: MBIO) has recently made significant strides in the battle against Waldenstrom macroglobulinemia (WM), a rare type of blood cancer. Their latest clinical trial results for MB-106, a
In a bold move that underscores the dynamism of the pharmaceutical industry, Ono Pharmaceutical Co., Ltd. has executed a major acquisition of Deciphera Pharmaceuticals Inc. The deal, valued at a hefty $2.4 billion, positions Ono strategically as a more influential player on the global stage,
The biopharma industry stands at the crossroads of innovation and necessity as it leans into the burgeoning field of immunology. With the global immunology market anticipated to grow exponentially in the coming years, reaching numbers second only to oncology, major players and emerging startups
